ES2173948T3 - Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. - Google Patents

Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.

Info

Publication number
ES2173948T3
ES2173948T3 ES95909917T ES95909917T ES2173948T3 ES 2173948 T3 ES2173948 T3 ES 2173948T3 ES 95909917 T ES95909917 T ES 95909917T ES 95909917 T ES95909917 T ES 95909917T ES 2173948 T3 ES2173948 T3 ES 2173948T3
Authority
ES
Spain
Prior art keywords
hydrocarbamide
didesoxi
inosine
blends
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909917T
Other languages
English (en)
Inventor
Serge D Malley
Raul Jorge Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2173948T3 publication Critical patent/ES2173948T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO Y COMPOSICION PARA INHIBIR LA EXPANSION DE UN RETROVIRUS COMO EL VIH DE UNA POBLACION CELULAR HUMANA, EN LA QUE EL RETROVIRUS, COMO EL VIH, SE ENCUENTRA PRESENTE. LA EXPANSION DEL RETROVIRUS SE INHIBE MEDIANTE EL TRATAMIENTO DE LAS CELULAS CON UNA MEZCLA DE COMBINACION SINERGISTICA DE UN DIDEOXINUCLEOSIDO, EXCLUYENDO AZT E HIDROXICARBAMIDA.
ES95909917T 1993-12-20 1994-12-20 Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. Expired - Lifetime ES2173948T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/169,253 US5521161A (en) 1993-12-20 1993-12-20 Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Publications (1)

Publication Number Publication Date
ES2173948T3 true ES2173948T3 (es) 2002-11-01

Family

ID=22614846

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909917T Expired - Lifetime ES2173948T3 (es) 1993-12-20 1994-12-20 Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.

Country Status (13)

Country Link
US (2) US5521161A (es)
EP (1) EP0735890B1 (es)
AT (1) ATE216245T1 (es)
AU (1) AU1821295A (es)
CA (1) CA2179627C (es)
DE (1) DE69430440T2 (es)
DK (1) DK0735890T3 (es)
ES (1) ES2173948T3 (es)
OA (1) OA10721A (es)
PT (1) PT735890E (es)
TW (1) TW283645B (es)
WO (1) WO1995017899A2 (es)
ZA (1) ZA949219B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
WO1993012782A1 (en) 1991-10-31 1993-07-08 Elford Howard L Method of treating viral diseases
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US6677310B1 (en) * 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
WO1996002554A1 (en) * 1994-07-15 1996-02-01 Gruppo Lepetit S.P.A. Dinucleoside-5',5'-pyrophosphates
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6511848B2 (en) * 1996-04-17 2003-01-28 Winfried Albert Process for producing and multiplying lymphocytes
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6218386B1 (en) 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
AU743942B2 (en) * 1997-03-20 2002-02-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
US6140368A (en) * 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
ATE413881T1 (de) * 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
KR100286373B1 (ko) * 1997-10-17 2001-04-16 윤종용 적외선 데이터 통신을 위한 휴대용 컴퓨터
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US6015796A (en) * 1998-03-11 2000-01-18 Zeria Pharmaceutical Co., Ltd. Method for treating AIDS
US6251874B1 (en) * 1998-03-26 2001-06-26 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
MXPA00012842A (es) * 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
WO2000045844A1 (en) * 1999-02-03 2000-08-10 Franco Lori Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
US6020325A (en) * 1999-03-09 2000-02-01 Zeria Pharmaceutical Co., Ltd. Method for inhibiting replication of HIV
AU774492B2 (en) 1999-07-22 2004-07-01 Celmed Oncology (Usa) Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
DE60015568D1 (de) 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
NL1012825C2 (nl) * 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
EP1359921A4 (en) * 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
US20050250728A1 (en) * 2002-05-23 2005-11-10 Shanta Bantia Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US5110600A (en) * 1988-01-25 1992-05-05 The Regents Of The University Of California Method of treating viral infections with amino acid analogs
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5300059A (en) * 1991-11-19 1994-04-05 Hydro Slip Technologies Inc. Bloodbag and method of making same
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
ATE216245T1 (de) 2002-05-15
AU1821295A (en) 1995-07-17
EP0735890A1 (en) 1996-10-09
CA2179627C (en) 2000-02-22
PT735890E (pt) 2002-09-30
US5521161A (en) 1996-05-28
CA2179627A1 (en) 1995-07-06
DE69430440D1 (de) 2002-05-23
WO1995017899A2 (en) 1995-07-06
ZA949219B (en) 1995-08-01
US5736527A (en) 1998-04-07
DK0735890T3 (da) 2002-08-05
WO1995017899A3 (en) 1995-08-10
OA10721A (en) 2002-12-09
TW283645B (es) 1996-08-21
EP0735890B1 (en) 2002-04-17
DE69430440T2 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
ES2173948T3 (es) Mezclas de 2&#39;,3&#39;-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
ES2183937T3 (es) Inhibidores de la adhesion celular.
GT200000198A (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos.
ES2095017T3 (es) Composicion cosmetica o farmaceutica que comprende en asociacion una peroxidasa y un agente antioxigeno singulete.
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
ES2174920T3 (es) Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno.
ES2104710T3 (es) Alteracion del ritmo y el tipo de crecimiento de pelo.
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
ES2012809B3 (es) Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen.
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2082872T3 (es) Composiciones antiglaucoma que contienen 3-arilcarbonil-1-aminoalquil--1h-indol.
MX9703648A (es) Metodos y composiciones para el acondicionamiento de la piel y el cabello.
BR9711647A (pt) Novos derivados de ácido dicafeoilquìmico, seu uso, composições com os mesmos e métodos de tratamento usando-os.
ES2000871A6 (es) Un procedimiento para producir un copolimero de bloques selectivamente hidrogenado y fuoncionalizado
ES2051675T3 (es) Inhibidores de protorfirinogeno y su uso en composiciones para detectar y tratar tumores.
BR0308431A (pt) Parecoxib sódico cristalino
CY1104971T1 (el) Παρασκευασμα αποϊνιδοτιδιου και g-csf και η χρηση του για να κινητοποιει αιμοποιητικους προγονους
ES2061447T3 (es) Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas.
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 735890

Country of ref document: ES